Welcome to our dedicated page for NOMAD POWER SOLUTIONS SEC filings (Ticker: LIXT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on NOMAD POWER SOLUTIONS's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into NOMAD POWER SOLUTIONS's regulatory disclosures and financial reporting.
Felix Lourdes reported acquisition or exercise transactions in this Form 4 filing.
LIXTE Biotechnology Holdings director Felix Lourdes received a grant of 30,000 restricted share units (RSUs) under the company’s 2020 Stock Incentive Plan. The RSUs represent the right to receive an equal number of common shares upon vesting, and the performance conditions for these 30,000 RSUs have been satisfied.
After this award, Lourdes holds a total of 55,000 RSUs, including 25,000 RSUs that have already vested. The grant was a compensation award with no cash paid per share.
Lixte Biotechnology Holdings, Inc. has completed its merger with NOMAD Transportable Power Systems, making NOMAD a wholly owned subsidiary and shifting the business toward mobile, utility-grade battery energy storage systems.
As merger consideration, NOMAD stockholders received 2,992,041 shares of common stock and 50,366.07 shares of new Series D Non-Voting Convertible Preferred Stock, which are convertible into up to 50,366,070 common shares at a $1.00 conversion price after stockholder approval. The company is changing its name to Nomad Power Solutions, Inc. effective July 3, 2026, and its NASDAQ ticker from LIXT to NMAD effective July 6, 2026.
The Series D Preferred Stock carries a $1,000 liquidation value per share and will accrue a 7% annual cash dividend, payable quarterly, if required stockholder approval is not obtained within one year. Lixte’s board also appointed NOMAD CEO John Travaglini as a director and approved bylaw and charter changes to support the new capital structure and governance. Registration rights and stockholder support agreements were entered into, and the company will seek stockholder approval for conversion of the preferred stock, an increase in authorized shares, and director elections at a meeting expected around September 4, 2026.
LIXTE Biotechnology Holdings filed an initial insider ownership report for director John Francis Travaglini. This Form 3 identifies him as a director, not an officer or 10% owner. The data provided shows no reported transactions or existing derivative positions at this time.
LIXTE Biotechnology Holdings, Inc. entered into a secured financing tied to its planned acquisition of NOMAD Transportable Power Systems. The company issued a $6.5 million Secured Promissory Note to NOMAD, secured by a first-priority security interest in substantially all of NOMAD’s assets.
The note’s proceeds will repay NOMAD’s existing loan with BPCP Investment Holdings and support NOMAD’s working capital and general corporate purposes as it scales to meet an active order pipeline. The note matures in 30 days, with automatic 30‑day extensions while the merger agreement remains in effect, and its principal will be offset against merger consideration at closing.
If the merger is terminated due to a breach by LIXTE, the note becomes repayable within six months; if terminated due to a breach by NOMAD, it is due within three days. LIXTE expects the NOMAD acquisition to close on or about July 1, 2026, after which the combined company will be renamed NOMAD Power Solutions, Inc. and trade under a new ticker symbol on Nasdaq.
LIXTE Biotechnology Holdings, Inc. signed a definitive Merger Agreement to acquire 100% of NOMAD Transportable Power Systems, a leader in mobile, utility-grade battery energy storage systems. Merger Sub will merge into NOMAD, which will become a wholly owned subsidiary, and the combined company plans to be renamed NOMAD Power Solutions.
At closing, NOMAD stockholders will receive a pro rata share of up to 50,500 shares of Series D Convertible Preferred Stock, with a $1,000 original issue price per share and convertible into up to 50,500,000 shares of common stock at $1.00 per share, plus up to 3,000,000 shares of common stock. The preferred stock will be non-voting until stockholders approve its conversion and an increase in authorized shares.
The merger is subject to conditions, including LIXTE having at least $16.5 million in unrestricted cash, Nasdaq listing of the Exchange Common Shares, and board changes adding NOMAD designees. NOMAD has shown rapid growth, with management citing approximately 175% revenue growth in 2025 and a projected approximately 135% increase in 2026, driven by strong demand for mobile, utility-grade BESS.
Lixte Biotechnology Holdings reports that Strategic EP, LLC and Alexander Chase Deitch together beneficially own 5.1% (774,902 shares) of Common Stock. The filing states the percentage is based on June 2, 2026 outstanding share count of 15,278,806, as reported in the Issuer's Prospectus on Form 424B5 filed June 4, 2026. The disclosure notes 545,521 warrants are issuable but contain a provision preventing exercise to the extent it would push ownership above 4.99%. The Reporting Persons filed a Joint Filing Agreement and signed the Schedule 13G on June 9, 2026.
Lixte Biotechnology Holdings, Inc. completed a registered direct offering of 2,366,503 shares of common stock and Pre-Funded Warrants to purchase 258,859 shares, generating gross proceeds of approximately $16.6 million before expenses. The securities were priced at $6.31 per share of common stock and $6.30 per Pre-Funded Warrant.
The Pre-Funded Warrants are immediately exercisable at $0.0001 per share and remain exercisable until fully exercised. The transaction, conducted under an effective shelf registration statement on Form S-3, closed on June 4, 2026, and the company plans to use the net proceeds for general corporate purposes and working capital.
Lixte is offering 2,366,503 shares of Common Stock and 258,859 Pre-Funded Warrants at $6.31 each. The offering is expected to close on or about June 4, 2026 and is intended to raise approximately $16,566,027.20 in gross proceeds. The Company states it will use net proceeds for working capital and general corporate purposes, including further clinical development of its lead compound, LB-100. Assuming exercise of the Pre-Funded Warrants, the prospectus shows 15,278,806 shares of Common Stock outstanding as of June 2, 2026.
Porter Stuart D reported acquisition or exercise transactions in this Form 4 filing.
LIXTE BIOTECHNOLOGY HOLDINGS, INC. director Stuart D. Porter reported receiving an equity grant of 25,000 shares of common stock in the form of restricted share units. The grant was made at a stated price of $0.00 per share, reflecting stock-based compensation rather than a market purchase.
The 25,000 RSUs were granted under the company’s 2020 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of common stock upon vesting, subject to continued service. The RSUs vest 25% on May 29, 2026, and 25% on the last date of each subsequent calendar quarter until fully vested. Following this grant, Porter directly holds 25,000 shares.
LIXTE Biotechnology Holdings, Inc. filed a regulatory ownership report identifying Stuart D Porter as a director. The provided data shows no reported transactions, no derivative positions, and no share movements, with all transaction counts and share amounts listed as zero.